C R Bard Inc  

(Public, NYSE:BCR)   Watch this stock  
Find more results for Abbott Products, Inc
168.87
+3.03 (1.83%)
After Hours: 168.01 -0.86 (-0.51%)
Dec 17, 4:11PM EST  
NYSE real-time data - Disclaimer
Currency in USD
Range 166.10 - 169.73
52 week 125.00 - 174.46
Open 166.29
Vol / Avg. 463,209.00/496,682.00
Mkt cap 12.58B
P/E 16.37
Div/yield 0.22/0.52
EPS 10.32
Shares 74.90M
Beta 0.71
Inst. own 91%
Jan 28, 2015
Q4 2014 C R Bard Inc Earnings Release (Estimated) - 4:00PM EST - Add to calendar
Dec 3, 2014
C R Bard Inc at Piper Jaffray Healthcare Conference
Nov 19, 2014
C R Bard Inc at Stifel Healthcare Conference
Oct 22, 2014
Q3 2014 C R Bard Inc Earnings Call - Webcast
Oct 22, 2014
Q3 2014 C R Bard Inc Earnings Release
More events from DailyFinance »    

Key stats and ratios

Q3 (Sep '14) 2013
Net profit margin 15.82% 22.62%
Operating margin 23.17% 34.38%
EBITD margin - 26.02%
Return on average assets 10.29% 15.01%
Return on average equity 29.51% 33.75%
Employees 13,000 -
CDP Score - -

Address

730 Central Avenue
MURRAY HILL, NJ 07974
United States - Map
+1-908-2778000 (Phone)
+1-908-2778412 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

C. R. Bard, Inc. (Bard) is engaged in the design, manufacture, packaging, distribution and sale of medical, surgical, diagnostic and patient care devices. As of December 31, 2011, the Company sold a range of products to hospitals, individual healthcare professionals, extended care facilities and alternate site facilities on a global basis. The Company participates in the markets for vascular, urology, oncology and surgical specialty products. Bard also has a product group of other products. Through subsidiaries and a joint venture, Bard markets its products to customers in over 100 countries outside the United States. The Company�s principal international markets were in Europe and Japan as of December 31, 2011. On November 10, 2011, Bard acquired Medivance, Inc. On December 16, 2011, the Company acquired Lutonix, Inc.

Officers and directors

Timothy M. Ring Chairman of the Board, Chief Executive Officer
Age: 56
Bio & Compensation  - Reuters
Trading Activity - Yahoo Finance
John H. Weiland President, Chief Operating Officer, Director
Age: 58
Bio & Compensation  - Reuters
Trading Activity - Yahoo Finance
Christopher S. Holland Chief Financial Officer, Senior Vice President
Age: 47
Bio & Compensation  - Reuters
Peter M. Kreindler Senior Vice President, General Counsel, Secretary
Age: 67
Bio & Compensation  - Reuters
John A. DeFord Ph.D. Senior Vice President - Science, Technology and Clinical Affairs
Age: 52
Bio & Compensation  - Reuters
Frank Lupisella Jr. Vice President, Controller
Age: 53
Bio & Compensation  - Reuters
Bronwen K. Kelly Vice President - Human Resources
Age: 61
Bio & Compensation  - Reuters
Trading Activity - Yahoo Finance
Jim C. Beasley Group Vice President
Age: 50
Bio & Compensation  - Reuters
Patricia G. Christian Vice President - Quality, Regulatory and Medical Affairs
Age: 53
Bio & Compensation  - Reuters
Timothy P. Collins Group Vice President
Age: 53
Bio & Compensation  - Reuters